Acquired Immunodeficiency Syndrome

5

Review clinical trials related to Acquired Immunodeficiency Syndrome. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Fuyang Jiedu Granules Plus Antiretroviral Therapy for HIV Immune Non-Responders With Spleen-Kidney Yang Deficiency

This pragmatic randomized controlled trial evaluates whether Fuyang Jiedu Granules combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure and spleen-kidney yang deficiency syndrome. Eligible participants are adults aged 18 to 60 years with HIV-1 infection, long-term viral suppression on ART, and persistently low CD4+ T-cell counts. A total of 240 participants will be randomized 1:1 to receive Fuyang Jiedu Granules plus ART or ART alone. Treatment lasts 48 weeks, followed by 48 weeks of follow-up. The primary outcomes are absolute CD4+ T-cell count and immune reconstitution response rate. Secondary outcomes include immune homeostasis markers, T-cell activation and Treg proportion, thymic output and inflammation-related markers, HIV RNA viral load, quality of life, clinical symptom scores, all-cause mortality, and safety.

Participants needed: 240
Trial details
Age: 18-60Biological sex: AllType: InterventionalSponsor: Beijing University of Chinese MedicineUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

Not listed

Status: Not yet recruiting

Qiling Yiqi Tablets Plus Antiretroviral Therapy for HIV Immune Non-responders With Lung-Spleen Qi Deficiency

This pragmatic randomized controlled trial evaluates whether Qiling Yiqi Tablets combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure and lung-spleen qi deficiency syndrome. Eligible participants are adults aged 18 to 60 years with HIV-1 infection, long-term viral suppression on ART, and persistently low CD4+ T-cell counts. A total of 240 participants will be randomized 1:1 to receive Qiling Yiqi Tablets plus ART or ART alone. Treatment lasts 48 weeks, followed by 48 weeks of follow-up. The primary outcomes are absolute CD4+ T-cell count and immune reconstitution response rate. Secondary outcomes include immune homeostasis markers, T-cell activation and Treg proportion, thymic output and inflammation-related markers, HIV RNA viral load, quality of life, clinical symptom scores, all-cause mortality, and safety.

Participants needed: 240
Trial details
Age: 18-60Biological sex: AllType: InterventionalSponsor: Beijing University of Chinese MedicineUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

Not listed

Status: Recruiting

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.

Participants needed: 100
Trial details
Phase: Phase 2Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 12, 2026Locations: 1
Eligibility criteria

Patients ≥ 2 years. English and non-English speaking patients are eligible. [+8]

Patients receiving prednisone > 0.5 mg/kg/day at time of enrollment, or have rec... [+2]

Status: Not yet recruiting

A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of HIV/AIDS Complicated With Infection

The goal of this observational study is to determine the incidence and spectrum of opportunistic infections among Chinese HIV/AIDS patients at this stage, to find intervention targets, to construct an early warning prediction model, and to give an individualized program with integrated immune function to obtain salvage opportunities for patients.The main questions it aims to answer are: * Describe the populations and characteristics of pathogenic microorganisms involved in HIV co-infection, map the spatial and temporal changes in the infection system of pathogenic microorganisms, and evaluate their impact on disease regression. * Explore the mechanism of interaction between pathogenic microorganisms and host autoimmune deficiencies. * Discover early warning and predictive markers and immunological indicators of pathogenic microorganisms, and explore new technologies and programs to reduce the mortality rate of infection.

Participants needed: 500
Trial details
Age: 18-70Biological sex: AllType: ObservationalSponsor: Zhejiang UniversityUpdated: Mar 4, 2024
Eligibility criteria

Sign the informed consent form. [+2]

Status: Not yet recruiting

Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity

To investigate the efficacy and tolerability of the regimen of dolutegravir plus lamivudine in HIV infected adults who are virologically suppressed and with evidence of TDF toxicity.

Participants needed: 100
Trial details
Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Public Health Clinical CenterUpdated: Aug 9, 2022
Eligibility criteria

Female subjects were required to meet one of the following criteria: 1) Incapaci... [+4]

Women who are pregnant or breastfeeding or plan to become pregnant or breastfeed... [+8]